Radius Health (RDUS) Receiving Somewhat Positive News Coverage, Accern Reports
Media headlines about Radius Health (NASDAQ:RDUS) have trended somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Radius Health earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.3100605888244 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- Zacks: Brokerages Anticipate Radius Health, Inc. (RDUS) Will Announce Quarterly Sales of $15.90 Million (americanbankingnews.com)
- Radius Health, Inc. (RDUS) Expected to Announce Earnings of -$1.28 Per Share (americanbankingnews.com)
- First Week of RDUS April 2018 Options Trading (nasdaq.com)
- Analyst Observation On 2 Stocks: Radius Health, Inc. (RDUS), Intel Corporation – registrarjournal.com (registrarjournal.com)
- Celgene Corporation (CELG) and Radius Health, Inc. (RDUS) Go Head-to-head – StockNewsGazette (stocknewsgazette.com)
A number of research analysts have issued reports on the stock. Canaccord Genuity set a $85.00 target price on shares of Radius Health and gave the company a “buy” rating in a report on Monday, July 17th. ValuEngine upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Jefferies Group LLC dropped their target price on shares of Radius Health from $40.00 to $34.00 and set a “hold” rating for the company in a research report on Tuesday, May 2nd. Cowen and Company downgraded shares of Radius Health from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 2nd. Finally, Cantor Fitzgerald set a $58.00 target price on shares of Radius Health and gave the stock a “buy” rating in a research report on Sunday, July 23rd. Two research analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $53.60.
Shares of Radius Health (NASDAQ RDUS) traded up 0.77% on Wednesday, hitting $37.90. The stock had a trading volume of 163,029 shares. Radius Health has a 52 week low of $31.58 and a 52 week high of $59.22. The firm has a 50 day moving average price of $40.73 and a 200-day moving average price of $39.89. The company’s market cap is $1.65 billion.
Radius Health (NASDAQ:RDUS) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by $0.23. The company had revenue of $0.98 million during the quarter, compared to the consensus estimate of $1.96 million. During the same quarter last year, the business posted ($1.01) earnings per share. Analysts anticipate that Radius Health will post ($5.51) EPS for the current year.
In other news, major shareholder Growth N. V. Biotech acquired 150,000 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The shares were bought at an average price of $34.97 per share, with a total value of $5,245,500.00. Following the acquisition, the insider now directly owns 5,113,799 shares in the company, valued at approximately $178,829,551.03. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Growth N. V. Biotech acquired 60,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 16th. The shares were purchased at an average cost of $35.98 per share, for a total transaction of $2,158,800.00. Following the acquisition, the insider now owns 5,248,799 shares in the company, valued at $188,851,788.02. The disclosure for this purchase can be found here. Company insiders own 15.00% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Radius Health (RDUS) Receiving Somewhat Positive News Coverage, Accern Reports” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/08/30/radius-health-rdus-receiving-somewhat-positive-news-coverage-accern-reports.html.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Stock Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related stocks with our FREE daily email newsletter.